Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis

Oncologist

Volumn 21, Issue 6, 2016, Pages 708-715

  Yin, Ming ^a   Joshi, Monika ^a   Meijer, Richard P ^b,c   Glantz, Michael ^a   Holder, Sheldon ^a   Harvey, Harold A ^a   Kaag, Matthew ^a   Van De Putte, Elisabeth E Fransen ^b   Horenblas, Simon ^b   Drabick, Joseph J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bladder cancer; Chemotherapy; Neoadjuvant; Platinum; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CYSTECTOMY; DATA EXTRACTION; HUMAN; META ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84975292831     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0440     Document Type: Review

References (44)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Chavan S, Bray F, Lortet-Tieulent J et al. International variations in bladder cancer incidence and mortality. Eur Urol 2014;66:59-73.
3. Witjes JA, Compérat E, Cowan NC et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 2014;65:778-792.
4. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl JMed 2003;349:859-866.
5. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol 2011;29: 2171-2177.
6. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and metaanalysis. Lancet 2003;361:1927-1934.
7. Advanced Bladder Cancer (ABC) Metaanalysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48:202-205; discussion 205-206.
8. Winquist E, Kirchner TS, Segal R et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J Urol 2004;171:561-569.
9. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-4608.
10. Tierney JF, Stewart LA, Ghersi D et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
11. Natale RB, Grossman HB, Blumenstein B et al. SWOG 8710 (int-0080): Randomized phase III trial of neoadjuvant MVAC 1 cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc Am Soc Clin Oncol 2001;20: 2a[Abstract 3].
12. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. Lancet 1999; 354:533-540.
13. Rintala E, Hannisdahl E, Fosså SD et al. Neoadjuvant chemotherapy in bladder cancer: A randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol 1993;27:355-362.
14. Malmström PU, Rintala E, Wahlqvist R et al. Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. J Urol 1996;155:1903-1906.
15. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic cystectomy trial 2. Scand J Urol Nephrol 2002;36:419-425.
16. Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur Urol 2004;45:297-303.
17. Dash A, Pettus JA, Herr HW et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience. Cancer 2008;113: 2471-2477.
18. Pal SK, Ruel NH, Wilson TG et al. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer 2012;10:246-250.
19. Alva AS, Tallman CT, He C et al. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: A multidisciplinary approach. Cancer 2012;118:44-53.
20. Galsky MD, Pal SK, Chowdhury S et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Cancer 2015;121:2586-2593.
21. Fairey AS, Daneshmand S, Quinn D et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: Aretrospective analysis fromtheUniversity of Southern California. Urol Oncol 2013;31:1737-1743.
22. Zargar H, Espiritu PN, Fairey AS et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015; 67:241-249.
23. Wallace DM, Raghavan D, Kelly KA et al. Neoadjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991;67:608-615.
24. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 1995;153: 964-973.
25. Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-3583.
26. Bassi P, Pappagallo GL, Sperandio P. Neoadjuvant mvac chemotherapy of invasive bladder cancer: Results of a multicenter phase III trial. J Urol 1999; 161:264A.
27. Sengeløv L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 2002;41:447-456.
28. Osman MA, Gabr AM, Elkady MS. Neoadjuvant chemotherapy versus cystectomy in management of stages II, and III urinary bladder cancer. Archivio Italiano di Urologia, Andrologia 2014;86:278-283.
29. Kitamura H, Tsukamoto T, Shibata T et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine andcisplatin followedby radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan clinical oncology group study jcog0209. Ann Oncol 2014;25:1192-1198.
30. Khaled HM, Shafik HE, Zabhloul MS et al. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: Effect on survival and bladder preservation. Clin Genitourin Cancer 2014; 12:e233-e240.
31. Weight CJ, Garcia JA, Hansel DE et al. Lack of pathologic down-staging with neoadjuvant chemotherapy formuscle-invasive urothelial carcinoma of the bladder: A contemporary series. Cancer 2009; 115:792-799.
32. Kaneko G, Kikuchi E, Matsumoto K et al. Neoadjuvant gemcitabine plus cisplatin for muscleinvasive bladder cancer. Jpn J Clin Oncol 2011;41: 908-914.
33. Yeshchina O, Badalato GM, Wosnitzer MS et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology 2012;79:384-390.
34. Meijer RP, Nieuwenhuijzen JA, Meinhardt W et al. Response to induction chemotherapy and surgery in non-organ confined bladder cancer: A single institution experience. Eur J Surg Oncol 2013; 39:365-371.
35. Lee FC, Harris W, Cheng HH et al. Pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv Urol 2013;2013: 317190.
36. Kawamura N, Matsushita M, Okada T et al. Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle invasive bladder cancer [in Japanese]. Hinyokika Kiyo 2013;59:277-281.
37. Iwasaki K, Obara W, Kato Y et al. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer. Jpn J Clin Oncol 2013;43:193-199.
38. Reardon ZD, Patel SG, Zaid HB et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: A sign of changing tides. Eur Urol 2015;67: 165-170.
39. Choueiri TK, Jacobus S, Bellmunt J et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;32:1889-1894.
40. Plimack ER, Hoffman-Censits JH, Viterbo R et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment formuscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014;32:1895-1901.
41. Dogliotti L, Cartenì G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial. Eur Urol 2007;52:134-141.
42. Yuh BE, Ruel N, Wilson TG et al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol 2013;189:1682-1686.
43. Petrelli F, Coinu A, Cabiddu M et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: Ameta-analysis. Eur Urol 2014; 65:350-357.
44. Rosenblatt R, Sherif A, Rintala E et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscleinvasive urothelial bladder cancer. Eur Urol 2012;61: 1229-1238.